You are here

MICROBIOTIX, INC.

Company Information
Address
1 Innovation Dr
Worcester, MA 01605-4307
United States



Information

DUNS: 158864715

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

    Amount: $299,449.00

    Abstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermo ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  2. Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy

    Amount: $300,000.00

    Abstract Enterovirus D68 (EV-D68), a highly contagious non-polio enterovirus, caused the 2014 outbreak affecting thousands of people in multiple countries, including the US, Canada and Europe. Histori ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  3. Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis

    Amount: $298,481.00

    Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis Summary: Despite the eradication of poliovirus in the US and Europe more than 20 years ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  4. Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype

    Amount: $298,483.00

    Summary: Hepatitis B virus (HBV) is a small DNA virus that chronically infects 240 million people worldwide, resulting in over 650 thousand deaths annually. HBV-induced fatalities typically result fro ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  5. Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

    Amount: $1,991,933.00

    Summary/Abstract The overall objective of this project is to develop new, potent, selective antimalarials that act through a novel mechanism of blocking the plasmodial surface anion channel (PSAC), a ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  6. Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis

    Amount: $1,999,559.00

    Summary/AbstractThe overall objective of this project is to develop a novel chemical class of tuberculosis (TB) therapeutic agents, the spectinamide series, for use against MDR and XDR strains of Myco ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  7. Optimization of novel pyranopyridine efflux pump inhibitors

    Amount: $1,968,757.00

    ABSTRACT The inadequacy of current treatment options to cure infections caused by MDR Gram-negative pathogens results in high rates of morbidity and mortality along with their concomitant treatment co ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  8. Discovery of Zika virus therapeutics using a replicon assay

    Amount: $584,970.00

    ABSTRACT The Zika virusZIKVis the cause of an explosive pandemic of infections across South and Central Americathe Caribbeanand the southeastern region of the United StatesZIKV is a flavivirusa family ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  9. Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy

    Amount: $595,561.00

    Summary Since its discovery inLassa virusLASVa bi segmented RNA virus from the family Arenaviridaehas been recognized as the cause of disease affecting a quarter million people per yearresulting indea ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  10. EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae

    Amount: $596,852.00

    Project SummaryThe CDC lists MDR Neisseria gonorrhoeaeNgas one of the three most urgent antibiotic resistance threats in the United StatesA Gram negative fastidious organismNg causes gonorrheathe seco ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government